Private Advisor Group LLC Lowers Stock Holdings in Tenet Healthcare Corporation $THC

Private Advisor Group LLC lowered its stake in Tenet Healthcare Corporation (NYSE:THC) by 78.7% during the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 1,512 shares of the company’s stock after selling 5,598 shares during the period. Private Advisor Group LLC’s holdings in Tenet Healthcare were worth $285,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds have also added to or reduced their stakes in the stock. Swedbank AB grew its position in Tenet Healthcare by 14.7% during the 4th quarter. Swedbank AB now owns 146,133 shares of the company’s stock valued at $29,040,000 after purchasing an additional 18,750 shares during the last quarter. Brandywine Global Investment Management LLC raised its holdings in Tenet Healthcare by 20.5% in the fourth quarter. Brandywine Global Investment Management LLC now owns 126,248 shares of the company’s stock worth $25,088,000 after buying an additional 21,435 shares during the last quarter. M&T Bank Corp lifted its stake in shares of Tenet Healthcare by 1,944.8% in the fourth quarter. M&T Bank Corp now owns 104,304 shares of the company’s stock worth $20,727,000 after buying an additional 99,203 shares in the last quarter. Cerity Partners LLC grew its holdings in shares of Tenet Healthcare by 8.4% during the fourth quarter. Cerity Partners LLC now owns 156,141 shares of the company’s stock valued at $31,028,000 after buying an additional 12,060 shares during the last quarter. Finally, Sivia Capital Partners LLC bought a new stake in shares of Tenet Healthcare during the second quarter valued at approximately $290,000. 95.44% of the stock is owned by institutional investors.

Insider Transactions at Tenet Healthcare

In other news, Director J Robert Kerrey sold 5,638 shares of the company’s stock in a transaction dated Thursday, May 28th. The shares were sold at an average price of $174.52, for a total transaction of $983,943.76. Following the completion of the sale, the director owned 16,804 shares of the company’s stock, valued at $2,932,634.08. This represents a 25.12% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Nadja West sold 3,000 shares of the firm’s stock in a transaction that occurred on Wednesday, May 27th. The stock was sold at an average price of $177.35, for a total transaction of $532,050.00. Following the completion of the transaction, the director directly owned 24,805 shares in the company, valued at approximately $4,399,166.75. The trade was a 10.79% decrease in their position. The SEC filing for this sale provides additional information. Insiders own 0.97% of the company’s stock.

Tenet Healthcare Price Performance

Shares of THC opened at $194.89 on Friday. The firm has a fifty day simple moving average of $184.35 and a two-hundred day simple moving average of $197.48. The firm has a market cap of $16.79 billion, a PE ratio of 10.13, a P/E/G ratio of 1.61 and a beta of 1.27. The company has a current ratio of 1.36, a quick ratio of 1.30 and a debt-to-equity ratio of 1.96. Tenet Healthcare Corporation has a 1-year low of $146.60 and a 1-year high of $247.21.

Tenet Healthcare (NYSE:THC) last issued its quarterly earnings data on Thursday, April 30th. The company reported $4.82 EPS for the quarter, topping the consensus estimate of $4.21 by $0.61. The company had revenue of $5.37 billion during the quarter, compared to analyst estimates of $5.39 billion. Tenet Healthcare had a return on equity of 25.55% and a net margin of 7.94%.Tenet Healthcare’s revenue was up 2.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $4.36 earnings per share. Tenet Healthcare has set its FY 2026 guidance at 16.380-18.68 EPS. On average, equities analysts anticipate that Tenet Healthcare Corporation will post 17.5 EPS for the current year.

Analyst Ratings Changes

THC has been the topic of several analyst reports. Wall Street Zen cut Tenet Healthcare from a “buy” rating to a “hold” rating in a research report on Saturday. Stephens decreased their price target on Tenet Healthcare from $275.00 to $260.00 and set an “overweight” rating for the company in a research note on Monday, May 4th. KeyCorp dropped their price objective on Tenet Healthcare from $250.00 to $225.00 and set an “overweight” rating on the stock in a research report on Friday, May 1st. Robert W. Baird reduced their price objective on Tenet Healthcare from $245.00 to $210.00 and set a “neutral” rating for the company in a report on Tuesday, May 5th. Finally, Royal Bank Of Canada lowered their target price on shares of Tenet Healthcare from $277.00 to $236.00 and set an “outperform” rating on the stock in a research note on Friday, May 1st. Eighteen equities research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $245.37.

About Tenet Healthcare

Tenet Healthcare Corporation (NYSE: THC) is a diversified American healthcare services company that owns and operates acute care hospitals and a broad range of outpatient facilities. Its portfolio includes general acute-care hospitals, specialty hospitals, ambulatory surgery centers, urgent care and diagnostic imaging centers, and other ancillary service locations. Tenet’s operations are oriented around delivering inpatient and outpatient clinical care across multiple medical specialties, with an emphasis on surgical services, emergency care, and advanced diagnostics.

In addition to facility-based care, Tenet provides integrated services designed to support clinical operations and improve patient access and care coordination.